BBNX Stock Forecast & Price Target

Beta Bionics is experiencing strong financial growth, as evidenced by their Q1 results which beat targets, a 54% increase in revenue year-over-year, and a standout gross margin of 59.5%. The company is also raising guidance for the full year, including increased revenue, gross margin, and a higher percentage of new patient starts through the pharmacy channel. With a solid pipeline and progress on their patch pump development, Beta Bionics is well positioned for continued success and market growth in the coming years.

Beta Bionics is facing headwinds as evident from the decline in NPS for the first quarter of 2026, which was better than expected but still a cause for concern. Additionally, the company's cash burn is expected to increase due to sales team expansion and management remains optimistic about the release of their patch product, but previous failures in the industry raise doubts about their ability to successfully launch it. Moreover, the company is yet to prove its ability to achieve sustainable profitability despite their positive outlook on gross margins.